Appointments to Expand Integrated Discovery Services

Integrated drug discovery and development services company, Concept Life Sciences has appointed Matilda Bingham as Site Director of its Alderley Park location in Cheshire and David Higton as Principal Scientist (Biotransformation and Metabolite Identification), also based at the same premises.

With over 15 years’ experience in both biotech and pharma environments, Matilda joins Concept from Redx Pharma, where she held positions as Head of Research and Operations as well as Executive Director of Oncology and Immunology. She also formerly worked for MSD Research Laboratories (part of Merck). With a PhD in Organic Chemistry, she has had numerous publications published and has managed programmes from hit-to-lead through to the clinic across a diverse range of target classes and disease areas.

With over 34 years of expertise in bioanalytical and biotransformation studies, including 23 years at Glaxo Group Research, now GlaxoSmithKline, where he supported pre-clinical, clinical and discovery investigations, for both non-GLP and GLP studies, David joins Concept from Cyprotex, where he was most recently Head of Analytical Sciences. Prior to this he was Analytical Team Leader at RedX Pharma, Vice President, Operations at Xceleron Inc and Principal Scientist at AstraZeneca, leading new scientific and technological development in regulatory bioanalysis.

Philip Payne, Chief Operating Officer, Concept Life Sciences, said: “With several years’ experience of managing multidisciplinary research projects in a pharmaceutical company environment, we are delighted to have appointed Matilda to head up our new Alderley Park site, which was established in September 2017. We are also pleased to welcome David, whose expertise will be a valuable addition to the analytical team.””